MannKind Corporation
corporate_fare Company Profile
MannKind Corporation (NASDAQ:MNKD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for MNKD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for MNKD spans 10-Q, 8-K, 4, 10-K.
Recent high-impact activity:
- MannKind 10-Q: Q3 Revenue Up 24% to $101.9M, Net Loss Widens to $23.2M
- MannKind Posts $23.2M Q3 Loss, Widening From $16.6M in Q1
- MannKind Licenses Technosphere to Rose Pharma for Inhaled GLP-1 Weight-Loss Drug
- MannKind Q2 Revenue Jumps 43% to $109M, Narrows Loss; Nintedanib DPI Phase 2 Planned
- MannKind's Inhaled IPF Drug Shows Clean Safety in Phase 1b, Phase 2 Enrolling
Financial Snapshot
Short Interest & Short Volume
10.31 days to coverFINRA reported short interest of 26,220,516 shares in MNKD as of the October 30, 2026 settlement, a 2.9% increase from the prior period — about 10.3 days to cover at its recent average daily volume. On November 20, 2026, 65.0% of MNKD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MNKD, detected from its recent SEC filings · based on capital-structure filings through 2026-07-24.
$50M Private Placement Priced at $3.89 · Proceeds Earmarked for $45M CVR Payment
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →